NICE Clears Alimera’s Iluvien For DME In Patients With Artificial Lens
This article was originally published in The Pink Sheet Daily
Executive Summary
Alimera Sciences’s Iluvien gets reimbursement clearance in the U.K. for diabetic macular edema patients unresponsive to other therapies with the help of a price discount and the lack of cataract side effects by limiting its use to patients with artificial lens.